Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer
-
Elez, Elena (Vall d'Hebron Institut d'Oncologia)
;
Hendlisz, A. (Institut Jules Bordet (Belgium)) ;
Delaunoit, T. (Centres Hospitaliers Jolimont (Belgium)) ;
Sastre Valera, Javier (Hospital Clínico San Carlos (Madrid)) ;
Cervantes, Andrés (Instituto de Investigación Sanitaria INCLIVA (València, Comunitat Valenciana)) ;
Varea, R. (Eli Lilly and Company (Spain)) ;
Chao, G. (Eli Lilly and Company (USA)) ;
Wallin, J. (Eli Lilly and Company (Suècia)) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
guest ::
Subscribe to this discussion. You will then receive all new comments by email.
